For decades, Biogen has built a legacy in neuroscience — having brought to market drugs that have changed lives for multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, and more. But ...

Biogen (NASDAQ:BIIB) is gearing up to announce its quarterly earnings on Thursday, 2025-10-30. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

The sale reduced Biogen to 0.03% of reported U.S. equity assets under management as of September 30. Top holdings after the filing: NASDAQ:MSFT: $164.85 million (13.9% of AUM) NASDAQ:AAPL: $122.68 ...

Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple Sclerosis ...

Biogen isn’t shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development deals have focused on enhancing the company’s ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. On May 1, it released fairly strong financial results for the first quarter ...

Across the recent three months, 18 analysts have shared their insights on Biogen (NASDAQ:BIIB), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Financial giants have made a conspicuous bearish move on Biogen. Our analysis of options history for Biogen (NASDAQ:BIIB) revealed 8 unusual trades. Delving into the details, we found 37% of traders ...

Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate of $3.42. Earnings rose 17% year over year on a reported basis, boosted by ...